[ad_1]
DON DIZON: Hi. Don Dizon. I’m a professor of medicine and professor of surgery at Brown University, and I treat pelvic cancers. And I’m here at ASCO ’23. And one of the studies that was presented was called the SHAPE trial and it involved people with early cervical cancer. It was a disease that was limited to the cervix – not very big.
And the approach is usually a very complicated surgery that you need specialized training for called a radical hysterectomy, where not only do they take the cervix and uterus, but the surgery extends to the side walls pelvic. And it can be a very complicated procedure with perioperative complications. But if you haven’t had cervical cancer, the standard procedure if you need to have your uterus removed is a simple hysterectomy. So it’s just a matter of removing the cervix and uterus and not doing this complicated procedure which extends to the pelvic region and the side wall.
This study tested this simpler procedure against the standard radical procedure and ultimately showed that at three years survival outcomes were the same and quality of life was better with a simple hysterectomy, particularly with respect to concerns the quality of sexual life.
DON DIZON: Hi, I’m Don Dizon. I’m a professor of medicine and professor of surgery at Brown University. And I treat pelvic cancer. One of the studies presented at ASCO 23 looked at overall survival outcomes if you add a checkpoint inhibitor to treatment for metastatic cervical cancer.
In this study, women with cervical cancer who had gone elsewhere or had metastasized were randomly assigned to a standard course of chemotherapy with or without a drug called bevacizumab, which blocks a specific protein called factor of vascular endothelial growth with or without a checkpoint inhibitor called pembrolizumab.
And these data, which are updated analyses, show that if we add pembrolizumab to this standard two- or three-drug combination, we improve overall survival by about a year. So these data really suggest, where available, that chemotherapy with pembrolizumab plus or minus the use of bevacizumab is the standard of care for people with metastatic cervical cancer.
DON DIZON: It’s Don Dizon. I’m a professor of medicine and professor of surgery at Brown University, and I treat pelvic cancers.
One of the studies presented here at ASCO ’23 was called the MIRASOL trial, and that study looked at people with recurrent ovarian cancer whose disease had come back soon after trying treatment. with a standard combination of platinum and taxane hopefully with. The intention to cure them. So if the disease comes back early, usually around six months or less, that situation is called platinum resistance.
The MIRASOL trial took people with platinum-resistant ovarian cancer and treated them with a new drug called mirvetuximab or standard chemotherapy. And this study showed overall survival benefits with this new drug, mirvetuximab, over standard chemotherapy, most importantly, in a select group of people whose tumors expressed a protein called folate receptor alpha. So again, for people with high folate receptor alpha ovarian cancer whose disease came back soon after chemotherapy, mirvetuxim
|
Sources 2/ https://www.webmd.com/cancer/asco-2023-special-report/20230609/treat-pelvic-cancers The mention sources can contact us to remove/changing this article |
[ad_2]